The Beta-thalassemia analysis mode on the G7 analyzer is used to confirm the identity of a hemoglobin variant for an HbA1c result and to screen for Beta-thalassemia and other hemoglobinopathies. For example, people with thalassemia can develop diabetes and a hemoglobin variant may interfere with their HbA1c result. Also, transfusion patients need to see a decrease in a specific hemoglobin variant. Furthermore, Hereditary Persistent Fetal Hemoglobin (HPFH) patients have high HbF above 20%.
Alternate methodologies (i.e. electrophoresis) usually require a combination of at least two techniques, one qualitative and one quantitative. As a result, these methodologies are time, labor and cost intensive. Tosoh would like you to know that the Beta-thalassemia mode on the G7 analyzer is a faster, easier and less expensive way for presumptive identification of hemoglobinopathies.
The University of Virginia Medical Center runs 600 samples/year, and uses the G7 Beta-thalassemia mode because it is faster than electrophoresis: “The Beta- thalassemia program on the G7 has reduced my turnaround time from 7 days to 24 hours”- Walter Oliveira.
Hemoglobinopathies may interfere with an HbA1c result which merits further investigation. Please contact your local System Sales Specialist to learn how you can help provide better patient care.